INSIGHTS ON DRUG DEVELOPMENT
-
Assessing Viability And Real-Time Apoptosis/Necrosis
Malignant gliomas are aggressive brain tumors that resist standard treatments. Discover why researchers focus on real-time cell death dynamics to develop targeted therapies and promising strategies.
-
Robust Database Characterizes And Optimizes Product Development
Integrating material characterization data with process parameters accelerates drug development, reduces empirical testing, and strengthens regulatory compliance.
-
Advancing Cell Therapies With Lipid Nanoparticles
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
Simplify Your Cell Culture Processes
Discover bioreactors that combine fast setup, robust design, and scalable performance to streamline cell culture workflows, which help you move from uncertainty to control, no matter your molecule.
-
Nanomedicine Modalities Find Path To Clinic Through Analytics5/16/2025
Lipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.
-
Lessons In Building Connected Lab Operations Across Development And GMP9/30/2026
Building connected operations across development and GMP environments removes bottlenecks and ensures data integrity. Explore practical insights to scale and standardize your lab workflows.
-
Improving The Efficiency And Quality Of Advanced Imaging And Analysis8/27/2025
Human-relevant models are transforming drug screening. Find out how overcoming 3D cell culture challenges with integrated innovations accelerates discovery and brings effective treatments to patients faster.
-
Transforming A Liquid Protein Solution Into A Solid Oral Dosage Form3/4/2025
Unlocking the potential of oral protein therapeutics requires innovative formulation and manufacturing strategies to overcome stability, absorption, and bioavailability challenges.
-
Assessing Developability And Designing Advanceable Formulations From The Start1/15/2026
Discover how early developability assessments and a quality-by-design approach can streamline formulation, reduce risk, and accelerate your path to successful, cost-effective drug development.
DRUG DEVELOPMENT SOLUTIONS
-
Our expertise and capabilities enable us to meet the complex technical challenges of pediatric products and provide you with a unique integrated development solution.
-
STELLARIS 8 FALCON FLIM Microscope
The contrast is clear. Lifetime imaging in an instant.
STELLARIS 8 FALCON (FAst Lifetime CONtrast) is the future of functional imaging. Harness the power of fluorescence lifetime to investigate cellular physiology and explore dynamics in living cells. STELLARIS 8 FALCON is a fully integrated solution for Fluorescence Lifetime Imaging (FLIM) and enables video-rate lifetime imaging acquisition for rapid kinetic studies in live cells.
STELLARIS 8 FALCON adds a new dimension of contrast to your imaging, opening the door to biosensing and tracking of interactions between proteins. FLIM information is now available for all modalities of the STELLARIS 8 system.
-
The LevMixer™ 10 L single-use mixing system is a low volume mixer designed for both upstream and downstream applications.
-
As part of Stevanato Group’s commitment to R&D, our analytical testing facilities focus on investigating physico-chemical properties of primary packaging materials and components and studying the interactions between container closure system and drugs. Stevanato Group relies on a multi-disciplinary team of highly skilled professionals, including, scientists, engineers, pharmaceutical chemists and biotechnologists. Their knowledge and experience covers a range of specialized areas including container closure systems and drug-delivery devices.
-
Gain insight into how faster structural elucidation is possible with integrated mass spectrometry workflows that combine intelligent data analysis, spectral matching, and automation.